AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025

 
• By Joseph Haas

Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.

R&D management
AbbVie is undertaking numerous R&D efforts to replace soon-diminishing Humira revenue

More from Strategy

More from Business